Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α

REFERENCES

• Peters JM. 1998. SCF and APC: the Yin and Yang of cell cycle regulated proteolysis. Curr Opin Cell Biol 10:759–768. http://dx.doi.org/10.1016/S0955-0674(98)80119-1.
   PubMedGoogle Scholar
• Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu Rev Biochem 67:425–479. http://dx.doi.org/10.1146/annurev.biochem.67.1.425.
   PubMed Web of Science ®Google Scholar
• Weissman AM. 1997. Regulating protein degradation by ubiquitination. Immunol Today 18:189–198. http://dx.doi.org/10.1016/S0167-5699(97)84666-X.
   PubMedGoogle Scholar
• Lipkowitz S, Weissman AM. 2011. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 11:629–643. http://dx.doi.org/10.1038/nrc3120.
   PubMed Web of Science ®Google Scholar
• Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG, Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657–661. http://dx.doi.org/10.1126/science.284.5414.657.
   PubMed Web of Science ®Google Scholar
• Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG, Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444–1446. http://dx.doi.org/10.1126/science.7660130.
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275. http://dx.doi.org/10.1038/20459.
   PubMed Web of Science ®Google Scholar
• Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20:5197–5206. http://dx.doi.org/10.1093/emboj/20.18.5197.
   PubMed Web of Science ®Google Scholar
• Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43–54. http://dx.doi.org/10.1016/S0092-8674(01)00507-4.
   PubMed Web of Science ®Google Scholar
• Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY. 2002. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417:975–978. http://dx.doi.org/10.1038/nature00767.
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG, Jr. 2001. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464–468. http://dx.doi.org/10.1126/science.1059817.
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472. http://dx.doi.org/10.1126/science.1059796.
   PubMed Web of Science ®Google Scholar
• Kaelin WG. 2007. von Hippel-Lindau disease. Annu Rev Pathol 2:145–173. http://dx.doi.org/10.1146/annurev.pathol.2.010506.092049.
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-Buck MR, Westphal H, Klausner RD, Linehan WM. 1997. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 94:9102–9107. http://dx.doi.org/10.1073/pnas.94.17.9102.
   PubMed Web of Science ®Google Scholar
• Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M, Regan M, Kaelin WG, Jr. 2006. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J 25:4650–4662. http://dx.doi.org/10.1038/sj.emboj.7601300.
   PubMed Web of Science ®Google Scholar
• Sala A. 2005. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer 41:2479–2484. http://dx.doi.org/10.1016/j.ejca.2005.08.004.
   PubMed Web of Science ®Google Scholar
• Ness SA. 2003. Myb protein specificity: evidence of a context-specific transcription factor code. Blood Cells Mol Dis 31:192–200. http://dx.doi.org/10.1016/S1079-9796(03)00151-7.
   PubMedGoogle Scholar
• Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S, Ishizaki R. 1988. Isolation of human cDNA clones of myb-related genes, A-myb and B-myb Nucleic Acids Res 16:11075–11089.
   PubMed Web of Science ®Google Scholar
• Toscani A, Mettus RV, Coupland R, Simpkins H, Litvin J, Orth J, Hatton KS, Reddy EP. 1997. Arrest of spermatogenesis and defective breast development in mice lacking A-myb. Nature 386:713–717. http://dx.doi.org/10.1038/386713a0.
   PubMedGoogle Scholar
• Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB, Cooke MP. 2005. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell 8:153–166. http://dx.doi.org/10.1016/j.devcel.2004.12.015.
   PubMed Web of Science ®Google Scholar
• Bessa M, Saville MK, Watson RJ. 2001. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator. Oncogene 20:3376–3386. http://dx.doi.org/10.1038/sj.onc.1204439.
   PubMedGoogle Scholar
• Charrasse S, Carena I, Brondani V, Klempnauer KH, Ferrari S. 2000. Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene 19:2986–2995. http://dx.doi.org/10.1038/sj.onc.1203618.
   PubMed Web of Science ®Google Scholar
• Katzen AL, Jackson J, Harmon BP, Fung SM, Ramsay G, Bishop JM. 1998. Drosophila myb is required for the G2/M transition and maintenance of diploidy. Genes Dev 12:831–843. http://dx.doi.org/10.1101/gad.12.6.831.
   PubMedGoogle Scholar
• Manak JR, Wen H, Van T, Andrejka L, Lipsick JS. 2007. Loss of Drosophila Myb interrupts the progression of chromosome condensation. Nat Cell Biol 9:581–587. http://dx.doi.org/10.1038/ncb1580.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Ishidao T, Nomura T, Shinagawa T, Tanaka Y, Yonemura S, Ishii S. 2008. A B-Myb complex containing clathrin and filamin is required for mitotic spindle function. EMBO J 27:1852–1862. http://dx.doi.org/10.1038/emboj.2008.118.
   PubMedGoogle Scholar
• Tanaka Y, Patestos NP, Maekawa T, Ishii S. 1999. B-myb is required for inner cell mass formation at an early stage of development. J Biol Chem 274:28067–28070. http://dx.doi.org/10.1074/jbc.274.40.28067.
   PubMed Web of Science ®Google Scholar
• Tarasov KV, Tarasova YS, Tam WL, Riordon DR, Elliott ST, Kania G, Li J, Yamanaka S, Crider DG, Testa G, Li RA, Lim B, Stewart CL, Liu Y, Van Eyk JE, Wersto RP, Wobus AM, Boheler KR. 2008. B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS One 3:e2478. http://dx.doi.org/10.1371/journal.pone.0002478.
   PubMed Web of Science ®Google Scholar
• Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI. 2004. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 6:1229–1235. http://dx.doi.org/10.1038/ncb1194.
   PubMed Web of Science ®Google Scholar
• Zhao WT, Zhou CF, Li XB, Zhang YF, Fan L, Pelletier J, Fang J. 2013. The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis. J Biol Chem 288:16588–16597. http://dx.doi.org/10.1074/jbc.M113.455121.
   PubMedGoogle Scholar
• Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU. 2004. Differentiating the functional role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2 alpha target gene in Hep3B and Kelly cells. FASEB J 18:1462–1464.
   PubMed Web of Science ®Google Scholar
• Okumura F, Zou W, Zhang DE. 2007. ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev 21:255–260. http://dx.doi.org/10.1101/gad.1521607.
   PubMed Web of Science ®Google Scholar
• Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW, Nakayama KI. 2004. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18:3055–3065. http://dx.doi.org/10.1101/gad.1252404.
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Ohh M, Kaelin WG, Jr. 1998. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A 95:11661–11666. http://dx.doi.org/10.1073/pnas.95.20.11661.
   PubMedGoogle Scholar
• Oh IH, Reddy EP. 1999. The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18:3017–3033. http://dx.doi.org/10.1038/sj.onc.1202839.
   PubMed Web of Science ®Google Scholar
• Lee S, Chen DYT, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD. 1996. Nuclear cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A 93:1770–1775. http://dx.doi.org/10.1073/pnas.93.5.1770.
   PubMedGoogle Scholar
• Johnson TK, Schweppe RE, Septer J, Lewis RE. 1999. Phosphorylation of B-Myb regulates its transactivation potential and DNA binding. J Biol Chem 274:36741–36749. http://dx.doi.org/10.1074/jbc.274.51.36741.
   PubMed Web of Science ®Google Scholar
• Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, Sullivan M. 2012. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40:D261–D270. http://dx.doi.org/10.1093/nar/gkr1122.
   PubMed Web of Science ®Google Scholar
• Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT. 2010. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70:1053–1062. http://dx.doi.org/10.1158/0008-5472.CAN-09-3722.
   PubMed Web of Science ®Google Scholar
• Haglund K, Dikic I. 2012. The role of ubiquitylation in receptor endocytosis and endosomal sorting. J Cell Sci 125:265–275. http://dx.doi.org/10.1242/jcs.091280.
   PubMed Web of Science ®Google Scholar
• Alwan HAJ, van Zoelen EJJ, van Leeuwen JEM. 2003. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 278:35781–35790. http://dx.doi.org/10.1074/jbc.M301326200.
   PubMedGoogle Scholar
• Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. 2003. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1:E83. http://dx.doi.org/10.1371/journal.pbio.0000083.
   PubMed Web of Science ®Google Scholar
• Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. 2003. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 3:31. http://dx.doi.org/10.1186/1471-2407-3-31.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Jr, Signoretti S. 2009. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69:4674–4681. http://dx.doi.org/10.1158/0008-5472.CAN-09-0146.
   PubMed Web of Science ®Google Scholar
• Okada M, Akimaru H, Hou DX, Takahashi T, Ishii S. 2002. Myb controls G(2)/M progression by inducing cyclin B expression in the Drosophila eye imaginal disc. EMBO J 21:675–684. http://dx.doi.org/10.1093/emboj/21.4.675.
   PubMedGoogle Scholar
• Beall EL, Manak JR, Zhou S, Bell M, Lipsick JS, Botchan MR. 2002. Role for a Drosophila Myb-containing protein complex in site-specific DNA replication. Nature 420:833–837. http://dx.doi.org/10.1038/nature01228.
   PubMedGoogle Scholar
• Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, Chen R, Washburn MP, Liu XS, DeCaprio JA. 2007. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell 26:539–551. http://dx.doi.org/10.1016/j.molcel.2007.04.015.
   PubMed Web of Science ®Google Scholar
• Wen H, Andrejka L, Ashton J, Karess R, Lipsick JS. 2008. Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex. Genes Dev 22:601–614. http://dx.doi.org/10.1101/gad.1626308.
   PubMed Web of Science ®Google Scholar
• Fung SM, Ramsay G, Katzen AL. 2002. Mutations in Drosophila myb lead to centrosome amplification and genomic instability. Development 129:347–359.
   PubMed Web of Science ®Google Scholar
• Garcia P, Frampton J. 2006. The transcription factor B-Myb is essential for S-phase progression and genomic stability in diploid and polyploid megakaryocytes. J Cell Sci 119:1483–1493. http://dx.doi.org/10.1242/jcs.02870.
   PubMed Web of Science ®Google Scholar
• Hughes MD, Kapllani E, Alexander AE, Burk RD, Schoenfeld AR. 2007. HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation. Cancer Cell Int 7:13. http://dx.doi.org/10.1186/1475-2867-7-13.
   PubMedGoogle Scholar
• Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. 2002. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247–255. http://dx.doi.org/10.1016/S1535-6108(02)00044-2.
   PubMed Web of Science ®Google Scholar
• Li M, Kim WY. 2011. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med 15:187–195. http://dx.doi.org/10.1111/j.1582-4934.2010.01238.x.
   PubMed Web of Science ®Google Scholar
• Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. 2005. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis 64:971–980.
   PubMed Web of Science ®Google Scholar
• Szade A, Grochot-Przeczek A, Florczyk U, Jozkowicz A, Dulak J. 2015. Cellular and molecular mechanisms of inflammation-induced angiogenesis. IUBMB Life 67:145–159. http://dx.doi.org/10.1002/iub.1358.
   PubMed Web of Science ®Google Scholar
• Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. 2010. Cancer and the complement cascade. Mol Cancer Res 8:1453–1465. http://dx.doi.org/10.1158/1541-7786.MCR-10-0225.
   PubMed Web of Science ®Google Scholar
• Pio R, Ajona D, Lambris JD. 2013. Complement inhibition in cancer therapy. Semin Immunol 25:54–64. http://dx.doi.org/10.1016/j.smim.2013.04.001.
   PubMedGoogle Scholar
• Kang CB, Hong Y, Dhe-Paganon S, Yoon HS. 2008. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 16:318–325. http://dx.doi.org/10.1159/000123041.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Klee CB, Bierer BE, Burakoff SJ. 1992. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 89:3686–3690.
   PubMed Web of Science ®Google Scholar
• Sewell TJ, Lam E, Martin MM, Leszyk J, Weidner J, Calaycay J, Griffin P, Williams H, Hung S, Cryan J, Sigal NH, Wiederrecht GJ. 1994. Inhibition of calcineurin by a novel FK-506-binding protein. J Biol Chem 269:21094–21102.
   PubMedGoogle Scholar
• Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. 1995. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377:441–446. http://dx.doi.org/10.1038/377441a0.
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905–909. http://dx.doi.org/10.1126/science.1715094.
   PubMed Web of Science ®Google Scholar
• Perrucci GL, Gowran A, Zanobini M, Capogrossi MC, Pompilio G, Nigro P. 2015. Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases. Cardiovasc Res 106:353–364. http://dx.doi.org/10.1093/cvr/cvv096.
   PubMedGoogle Scholar
• Deivanayagam CC, Carson M, Thotakura A, Narayana SV, Chodavarapu RS. 2000. Structure of FKBP12.6 in complex with rapamycin. Acta Crystallogr D Biol Crystallogr 56:266–271. http://dx.doi.org/10.1107/S0907444999016571.
   PubMedGoogle Scholar
• Khatua S, Peterson KM, Brown KM, Lawlor C, Santi MR, LaFleur B, Dressman D, Stephan DA, MacDonald TJ. 2003. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63:1865–1870.
   PubMed Web of Science ®Google Scholar
• Saarikangas J, Barral Y. 2011. The emerging functions of septins in metazoans. EMBO Rep 12:1118–1126. http://dx.doi.org/10.1038/embor.2011.193.
   PubMed Web of Science ®Google Scholar
• Weirich CS, Erzberger JP, Barral Y. 2008. The septin family of GTPases: architecture and dynamics. Nat Rev Mol Cell Biol 9:478–489. http://dx.doi.org/10.1038/nrm2407.
   PubMed Web of Science ®Google Scholar
• Craven RA, Hanrahan S, Totty N, Harnden P, Stanley AJ, Maher ER, Harris AL, Trimble WS, Selby PJ, Banks RE. 2006. Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 6:3880–3893. http://dx.doi.org/10.1002/pmic.200500811.
   PubMed Web of Science ®Google Scholar
• Gilden JK, Peck S, Chen YC, Krummel MF. 2012. The septin cytoskeleton facilitates membrane retraction during motility and blebbing. J Cell Biol 196:103–114. http://dx.doi.org/10.1083/jcb.201105127.
   PubMed Web of Science ®Google Scholar
• Osaka M, Rowley JD, Zeleznik-Le NJ. 1999. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci U S A 96:6428–6433. http://dx.doi.org/10.1073/pnas.96.11.6428.
   PubMed Web of Science ®Google Scholar
• Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M. 2007. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13:806–815. http://dx.doi.org/10.1158/1078-0432.CCR-06-1820.
   PubMed Web of Science ®Google Scholar